TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8003644
Drug: 6 million
Normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 million units of lymphoblastoid IFN-alpha daily for 2 weeks
Study: 2809902
Drug: Methionyl growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl growth hormone, 2 IU/m2 subcutaneously once daily (group 1)
Study: 2809902
Drug: Methionyl growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionyl growth hormone, 4 IU/m2/day (group 1B)
Study: 2809902
Drug: Authentic biosynthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Authentic biosynthetic growth hormone (group 2)
Study: 2809902
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (group 3)
Study: 1106217
Drug: Lithium combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium combined with major tranquilizers
Study: 31746743
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (Agent)
Study: 31746743
Drug: Standard drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug-coated balloon (SeQuent Please)
Study: 27746555
Drug: Esmolol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (500 μg/kg IV bolus followed by 100 μg/kg/min infusion)
Study: 27746555
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg IV bolus followed by 0.2 μg/kg/h infusion)
Study: 18586996
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment indicators
Study: 10445766
Drug: Intrathecal methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal methylprednisolone acetate (MPA), 60 mg administered four times at 1-week intervals.
Study: 10445766
Drug: Epidural methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural methylprednisolone acetate (MPA), 60 mg administered four times at 1-week intervals.
Study: 7829618
Drug: Finasteride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5 mg, orally, daily)
Study: 7829618
Drug: Spironolactone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (100 mg, orally, daily)
Study: 2791157
Drug: Ever-Young Pill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ever-Young Pill (EYP)
Study: 214701
Drug: Beta-Sitosterol 5.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Sitosterol 5.28 g
Study: 214701
Drug: Beta-Sitosterol 10.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-Sitosterol 10.56 g
Study: 7060328
Drug: 975‐mg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 975‐mg oral doses of aspirin
Study: 30049471
Drug: .04 taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: .04 taper instrumentation
Study: 30049471
Drug: .06 taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: .06 taper instrumentation
Study: 30049471
Drug: .08 taper
Approvals — FDA: no, EMA: no, PMDA: no
Description: .08 taper instrumentation
Study: 26786399
Drug: Ultra-low-dose estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose estriol vaginal gel 20 μg/g (T1)
Study: 26786399
Drug: Ultra-low-dose estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose estriol vaginal gel 50 μg/g (T2)
Study: 26786399
Drug: Ovestinon® (estriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovestinon® (estriol 500 μg/0.5 g) (R)
Study: 24942563
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shockwave therapy
Study: 20126672
Drug: Other agents
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other agents (control)
Study: 17617293
Drug: Generic azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Generic azithromycin (2 x 250 mg)
Study: 17617293
Drug: Branded azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Branded azithromycin (2 x 250 mg)
Study: 14693612
Drug: IV propacetamol
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV propacetamol 2 g (followed by 1 g)
Study: 14693612
Drug: IM morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM morphine 10 mg (followed by 5 mg)
Study: 14693612
Drug: Propacetamol vs
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol vs Morphine
Study: 9829638
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (SQV + ZDV)
Study: 8180293
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole 40 mg/day
Study: 8180293
Drug: Oral pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pantoprazole 60 mg and 80 mg
Study: 1106208
Drug: 0.5 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml/kg body weight of 95% ethanol
Study: 1106208
Drug: 1.0 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 ml/kg body weight of 95% ethanol
Study: 1106208
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg delta‐9‐tetrahydrocannabinol (THC)
Study: 1106208
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg delta‐9‐tetrahydrocannabinol (THC)
Study: 21617527
Drug: L-theanine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine (400 mg/d)
Study: 15005871
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of ethanol (0.8 g/kg for males and 0.7 g/kg for females)
Study: 15005871
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of ethanol (75% of the high dose)
Study: 8664090
Drug: Paracetamol/codeine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/codeine combination
Study: 6373097
Drug: atropine (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: atropine (two doses)
Study: 18256990
Drug: NMO-IgG antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMO-IgG antibody marker
Study: 15766322
Drug: Intracavernous administration
Normalized name: bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracavernous administration
Study: 15766322
Drug: All PDE5
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All PDE5 inhibitors
Study: 12828588
Drug: Chiron Hib/AlPO4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiron Hib/AlPO4 vaccine
Study: 12828588
Drug: VaxemHib (aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: VaxemHib (aluminum hydroxide adjuvant) vaccine
Study: 10898671
Drug: Piperacillin plus
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin plus tazobactam (monotherapy)
Study: 10898671
Drug: Piperacillin plus
Normalized name: Piperacillin
DrugBank: Piperacillin (DB00319)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Piperacillin plus tazobactam plus amikacin (combined therapy)
Study: 1505153
Drug: 6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg/kg of liquid ibuprofen
Study: 1505153
Drug: 10 to
Normalized name: RE-10 Topical Wash
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 to 15 mg/kg of liquid acetaminophen (mean dose 11.6 +/- 0.7)
Study: 6512582
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (vincristine/cyclophosphamide/dactinomycin and vincristine/doxorubicin/dacarbazine at six-week intervals for one year)
Study: 6512582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no adjuvant chemotherapy, evaluated at six-week intervals)
Study: 22997893
Drug: Penehyclidine hydrochloride
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Penequinine, Penehyclidine (DB16287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penehyclidine hydrochloride (0.01 mg/kg before anesthesia and 0.015 mg/kg in CPB)
Study: 14663031
Drug: Idebenone 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 120 mg tid
Study: 14663031
Drug: Idebenone 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 240 mg tid
Study: 14663031
Drug: Idebenone 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone 360 mg tid
Study: 14663031
Drug: Idebenone (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idebenone (combined treatment groups)
Study: 14663031
Drug: Placebo (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (combined treatment groups)
Study: 8339631
Drug: NIC SR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC SR 30 mg twice daily
Study: 8339631
Drug: NIC SR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC SR 45 mg twice daily
Study: 8339631
Drug: NIC SR
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NIC SR 60 mg twice daily
Study: 30289026
Drug: Blackadder blackcurrant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blackadder blackcurrant juice (500 mg polyphenols)
Study: 27323443
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (needling dorsal segment of the Governor Vessel, 7 spots below the spinous processes from T3 to T9)
Study: 27323443
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Omeprazole capsules, 20 mg twice a day for 8 weeks)
Study: 24142782
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of fluticasone 125 μg BID
Study: 24142782
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of fluticasone 250 μg BID
Study: 24142782
Drug: Fluticasone DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone DPI 500 μg BID
Study: 21875351
Drug: Oral GSH
Normalized name: GSH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral GSH supplementation (500 mg twice daily for 4 weeks)
Study: 12791001
Drug: Oral loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loperamide (12 mg daily, 4 mg t.d.s.)
Study: 12791001
Drug: Suppository loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository loperamide (12 mg daily, 6 mg b.d.)
Study: 12791001
Drug: Oral loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral loperamide
Study: 12791001
Drug: Suppository loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository loperamide
Study: 11273109
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (digitalis and diuretics)
Study: 2646188
Drug: urapidil 60
Normalized name: urapidil 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: urapidil 60 mg (morning and evening)
Study: 2646188
Drug: nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nifedipine retard 20 mg (morning and evening)
Study: 21235465
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of diclofenac sodium (75 mg/mL)
Study: 21235465
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of diclofenac sodium (75 mg/3 mL)
Study: 15966561
Drug: Early gonadotropin-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early gonadotropin-releasing hormone (GnRH) agonist cessation protocol with leuprorelin 0.5 mg for 10-14 days followed by high doses of gonadotropins.
Study: 15966561
Drug: Microdose flare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose flare protocol utilizing oral contraceptive priming followed by diluted doses of leuprorelin 50 microg twice daily and high doses of gonadotropins.
Study: 15966561
Drug: Baseline ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline ultrasound measurements predicting low response to IVF therapy.
Study: 9155717
Drug: CFTR cDNA-liposome
Normalized name: rsATP7A cDNA
DrugBank: rsATP7A cDNA (DB17854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFTR cDNA-liposome complexes delivered by topical application
Study: 9155717
Drug: CF subjects
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF subjects (combined treatment and control)
Study: 3492358
Drug: Cefadroxil 1
Normalized name: CEFADROXIL 1GM TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 1 g every 12 hours for a mean duration of 11 days
Study: 3492358
Drug: Co-trimoxazole 1
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 1 double-strength tablet every 12 hours for a mean duration of 13 days
Study: 27644672
Drug: Ginger (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger (500 mg capsules, 2 times a day for 10 days)
Study: 27644672
Drug: Chamomile (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile (500 mg capsules, 2 times a day for 10 days)
Study: 27644672
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine antiemetic regimen consisting of DMA capsules)
Study: 25399007
Drug: Aspirin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (200 mg before surgery, then 100 mg daily for up to 30 days after surgery)
Study: 25399007
Drug: Clonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.2 mg before surgery, then transdermal patch providing 0.2 mg/d for 72 hours after surgery)
Study: 25399007
Drug: Aspirin (presence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (presence of major bleeding)
Study: 22858211
Drug: Early switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early switch to duloxetine 60-120 mg/day
Study: 20394790
Drug: Conventional cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cigarette smoking (CC)
Study: 11799376
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered to mothers during pregnancy and lactation
Study: 11799376
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to mothers during pregnancy and lactation
Study: 6248395
Drug: Orciprenaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orciprenaline (10 mg)
Study: 31036105
Drug: Chloroquine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (250 mg twice daily per oral, 10 mg/kg/day)
Study: 31036105
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg daily per oral, 3.3 mg/kg/day)
Study: 23368510
Drug: Lixisenatide QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide QD (10 µg weeks 1-2, then 20 µg)
Study: 23368510
Drug: Liraglutide QD
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg)
Study: 20309523
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg daily, self-administered injections at bedtime for 12 months)
Study: 16505130
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) for 15 sessions
Study: 16505130
Drug: Sertraline (SSRI)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SSRI) with a maximum dosage of 150 mg
Study: 30697968
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment in addition to scaling and root planing (SRP)
Study: 22803428
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen Injection (CDI)
Study: 8961973
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for 5 years (20 mg/day orally)
Study: 8961973
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy for 2 years (20 mg/day orally)
Study: 31092125
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment addressing 2 or more factors
Study: 31092125
Drug: Single factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single factor treatment
Study: 26024828
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose S‐ILE (1 g/kg/d)
Study: 26024828
Drug: Control dose
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dose S‐ILE (3 g/kg/d)
Study: 28514547
Drug: Etoricoxib therapy
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib therapy
Study: 23031478
Drug: T1 (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: T1 (2.5 mg/kg)
Study: 23031478
Drug: T2 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: T2 (25 mg/kg)
Study: 23031478
Drug: T3 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 (250 mg/kg)
Study: 7496681
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose craniospinal irradiation (25 Gy) followed by a boost to the posterior fossa (total dose 55 Gy)
Study: 1657084
Drug: Enalapril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (2.5 mg)
Study: 18195565
Drug: Lopinavir/ritonavir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir plus zidovudine and lamivudine (triple-drug therapy)
Study: 16390349
Drug: MMX-budesonide tablets
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MMX-budesonide tablets (9 mg)
Study: 16390349
Drug: MMX-budesonide tablets
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MMX-budesonide tablets with food
Study: 16390349
Drug: MMX-budesonide tablets
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: MMX-budesonide tablets without food
Study: 22728908
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy (Control)
Study: 18030331
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (D)
Study: 11824302
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (locoregional thrombolysis and mechanical thrombectomy)
Study: 9488097
Drug: Lu 25-109
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu 25-109 at 150 mg tid for 7 days (fixed-dose MTD)
Study: 9488097
Drug: Lu 25-109
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu 25-109 at titrated doses (75 mg tid, 100%, 125%, and 150% of fixed dose MTD)
Study: 8072071
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg methylprednisolone plus 40 mg nifedipine daily (group 1)
Study: 8072071
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg methylprednisolone plus placebo daily (group 2)
Study: 25096918
Drug: Polyethylene glycol-electrolyte
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol-electrolyte lavage solution (PEG; CoLyte)
Study: 17131847
Drug: Perindopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril treatment
Study: 15126811
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg trospium twice daily
Study: 9801884
Drug: Povidone-iodine 4%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 4% solution
Study: 7831637
Drug: Inhaled lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lignocaine (20 mg)
Study: 28899262
Drug: Concurrent assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent assessment of misinformation narratives
Study: 28209296
Drug: Intravenous mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mitomycin (12 mg/m2 on day 1) or intravenous cisplatin (60 mg/m2 on days 1 and 29), with intravenous fluorouracil (1000 mg/m2 per day on days 1-4 and 29-32) and radiotherapy (50.4 Gy in 28 daily fractions)
Study: 28209296
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy (fluorouracil and cisplatin)
Study: 26439877
Drug: Selenium supplementation
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplementation (200 μg Se as Se yeast) daily for 6 months
Study: 17194267
Drug: Zonisamide (100-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (100-600 mg/day)
Study: 12932067
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anaesthesia with propofol and remifentanil
Study: 12848597
Drug: lercanidipine 10
Normalized name: lercanidipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lercanidipine 10 mg once daily
Study: 9483355
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (reviparin sodium, Clivarin) s.c. once daily with graduated elastic stockings (n = 359)
Study: 8460391
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (10 mg/kg body weight) administered 12 hours and 1 hour prior to operation